News & Updates
Showing Oncology articles
Showing
Awareness rising, yet breast cancer screening rates continue to lag behind
Many women in Malaysia are still hesitant to go for regular breast cancer screening despite being aware of its importance.
Awareness rising, yet breast cancer screening rates continue to lag behind
02 Oct 2025
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
Results from the phase III HARMONi trial presented at WCLC 2025 show that adding ivonescimab to chemotherapy prolongs progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
30 Sep 2025
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
Smoking, obesity, treatment duration, and pre-existing cardiac diseases may contribute to the development of cardiotoxicity among patients with cancer who are undergoing 5-fluorouracil (5-FU) chemotherapy, suggests a recent study.
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
29 Sep 2025
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.
